DLPIC
REGN icon

Davide Leone & Partners Investment Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-29,492
Closed -$18.4M – 23
2020
Q2 		$18.4M Buy
+29,492
New +$16.7M 1.94% 16

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Davide Leone & Partners Investment Company's REGN Position: Q3 2020 in Review

Davide Leone & Partners Investment Company sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 29,492 shares — an estimated $18.4M sold.

Davide Leone & Partners Investment Company first reported a position in REGN in Q2 2020 and held it in 1 quarter. The position peaked at $18.4M in Q2 2020. 908 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

  • Davide Leone & Partners Investment Company reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Davide Leone & Partners Investment Company sold 29,492 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $18.4M.
  • Davide Leone & Partners Investment Company first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Davide Leone & Partners Investment Company's Regeneron Pharmaceuticals position peaked at $18.4M in Q2 2020.
  • 908 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on Davide Leone & Partners Investment Company's 13F filing for Q3 2020, filed 16 Nov 2020.